I am very puzzled by Revenio’s valuation. The multiples of this former growth company have been pushed down to value stock levels. The market no longer believes the company will return to any kind of growth. There is zero confidence in new acquisitions; it is believed they will only destroy value. What stands out most is the balance sheet-based valuation. The P/B for this year is only 1.8x. Multiples like these haven’t been seen since the “rubber boat days.” However, the company is still generating decent profits, even if new acquisitions will dilute margins. In my opinion, the company still belongs among the quality stocks on the Helsinki Stock Exchange, with clear competitive advantages.
I bought the stock for my portfolio today at €13.40.
It took a moment to figure out. There was an extra zero there. It was confusing, as the same error was found elsewhere too. So, it is the IC100 in question.
A bit of speculation, but perhaps the USA has been requesting additional studies one after another. Even though the model isn’t specified, my spider sense says it’s the same device.
Just put the devices on sale without the USA and get money into the bank.
That seems to be the case. It’s strange that there is so little information available. Nothing really from the manufacturer. Could it be some kind of breakthrough product that has been long-awaited…
Quite a few new patents this year.
E.g. WO2026057923A1 – Air pulse tonometers – published March 19, 2026 WO2026047277A1 – An air pulse based tonometer – published March 5, 2026
This is likely what caused the positive momentum already on Friday, but I didn’t notice it until this morning while busy with Optomed. I’ll need to look into it more closely when I have time, but here is a quick comment for the morning.
@Juha_Kinnunen , I mentioned the approval iHealthscreen received for DRS Plus on the forum over a month ago, so it’s not exactly fresh news. Positive, certainly, absolutely.
Clearly the forum knows better, and the analyst has been on vacation. I suspect many others have been too. I wonder if some confirmation has come through now that the company is issuing a statement, or if they have also just returned from their vacation?
Something new regarding Icare will be announced in September at the trade fair in London. I won’t speculate any further, but at first glance, it just looks like an updated model.
I listened to that podcast where Jani Järvinen talked about how he makes money, for example, through share issues (subscription offerings).
Isn’t there a case like this in Revenio, where existing shareholders can subscribe for new shares at a price that is about 20% of the current share value?
Of course, this assumes that the market value wouldn’t drop after the share issue.
Owners and potential investors are getting a more detailed explanation of what’s going on.
With Visionix, there’s a new strategy and integration to handle.
There is certainly plenty to explain, as the market hasn’t been convinced at all by what has been shared so far, at least judging by the share price, which has collapsed by 1/3…
Capital Markets Day 2026
Revenio Group is pleased to invite analysts, investors, and media representatives to a Capital Markets Day on Tuesday, September 15, 2026, starting at 2:00 p.m. The event will be held in Helsinki at Sanomatalo (Töölönlahdenkatu 2) and can also be followed via a live webcast.
Revenio completed the acquisition of Visionix in May 2026. Following the acquisition, Revenio has focused on advancing integration and drafting a new joint strategy. At the Capital Markets Day, the company’s key personnel will provide an in-depth review of Revenio’s strategy.
Program
Jouni Toijala, CEO: Market
Erkki Tala, VP Products: Offering
Umberto Bargiggia, VP International Sales: Go-to-market
Revenio’s share price has started to head upward again over the last few weeks. The shock following the acquisition has faded.
Unfortunately, as an investor, I wasn’t in on the major hype during Revenio’s rapid rise, but I concluded that the company had been beaten down so far that the downside risks are quite small, and in a good scenario, the firm could double its share price over the next few quarters. So, I jumped on board this summer. Hopefully, I’m right.
However, I still haven’t done my homework very well regarding Revenio. What are the company’s biggest risks that could significantly weigh down the share price?
Actually, you already answered it yourself, but I see the acquisition specifically as the biggest risk. If for one reason or another the anticipated benefits are not achieved, I expect the market will once again “thank” the share price with a proper beating.